Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...

Objective Hydroxychloroquine (HCQ) is an antimalarial drug employed in the treatment of systemic lupus erythematosus (SLE).

Objective Lupus nephritis (LN) is a major complication and cause of death among patients with SLE. This research used in vivo and in vitro experiments to explore the therapeutic potential of metformin ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods A phase ...

Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...

1 Division of Rheumatology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA 2 Human Immunology and Immunotherapy Initiative (HI3), Department of Immunology, ...

1 West China Hospital affiliated Sichuan University, Department of Laboratory Medicine, Chengdu, China 2 West China Hospital affiliated Sichuan University, Department of Rheumatology, Chengdu, China 3 ...

Objective To evaluate the pregnancy outcomes in patients with systemic autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary Sjögren’s syndrome (pSS) and ...

Objective To character the molecular landscape of patients with type 1 and type 2 SLE by analysing gene expression profiles from peripheral blood. Methods Full transcriptomic RNA sequencing was ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...

Objective To evaluate the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE). Methods Patients (n=340) with SLE ≥4 ACR criteria (4–11, mean 7) with active ...